Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xeroderma Pigmentosum, Complementation Group D
|
111 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2006 | 2006 | ||||
Stomach Carcinoma
|
652 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Renal Cell Carcinoma
|
288 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Prostate carcinoma
|
1168 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.040 | 0.750 | 4 | 2006 | 2019 | ||||
Primary malignant neoplasm of lung
|
981 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.060 | 1.000 | 6 | 2005 | 2019 | ||||
Primary malignant neoplasm
|
1374 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.080 | 0.625 | 8 | 2009 | 2019 | ||||
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
|
23 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Non-Small Cell Lung Carcinoma
|
712 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.030 | 1.000 | 3 | 2006 | 2012 | ||||
Nasopharyngeal carcinoma
|
320 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Meningioma, benign, no ICD-O subtype
|
30 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Meningioma
|
43 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2010 | 2010 | ||||
Malignant Neoplasms
|
1641 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.080 | 0.625 | 8 | 2009 | 2019 | ||||
Malignant neoplasm of urinary bladder
|
316 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.020 | 1.000 | 2 | 2012 | 2014 | ||||
Malignant neoplasm of stomach
|
615 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Malignant neoplasm of prostate
|
1082 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.040 | 0.750 | 4 | 2006 | 2019 | ||||
Malignant neoplasm of lung
|
1142 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.060 | 1.000 | 6 | 2005 | 2019 | ||||
Malignant neoplasm of breast
|
3417 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.050 | 0.600 | 5 | 2005 | 2019 | ||||
Lymphoma, Non-Hodgkin
|
197 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2012 | 2012 | ||||
Liver carcinoma
|
942 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.020 | 1.000 | 2 | 2012 | 2018 | ||||
Leukemia, Myelocytic, Acute
|
6892 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||
Hodgkin Disease
|
148 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2011 | 2011 | ||||
Glioma
|
353 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Complete atrioventricular block
|
96 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2018 | 2018 | ||||
Colon Carcinoma
|
275 | 0.605 | 0.600 | 8 | 89978251 | missense variant | C/G | snv | 0.35 | 0.31 | 0.010 | 1.000 | 1 | 2013 | 2013 |